Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for negative symptoms of schizophrenia
NCT04531982Phase 3Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of pimavanserin in schizophrenia, sponsored by Acadia Pharmaceuticals. Started Aug 2020; status: completed.
02
Drugs
pimavanserin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04531982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04531982.